<DOC>
	<DOC>NCT01082120</DOC>
	<brief_summary>The purpose of this study is to determine whether administration of AZD1656 will affect the pharmacokinetics of Pioglitazone and vice versa in patients with Type 2 Diabetes Mellitus.</brief_summary>
	<brief_title>Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Patients with confirmed Type 2 Diabetes Mellitus for at least 1 year and treated with metformin alone or metformin and one other oral antidiabetic drug Body mass index between ≥19 and ≤42 kg/m2. Impaired renal function Clinically significant illness or clinically relevant trauma.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Pioglitazone</keyword>
</DOC>